Home » Topics » BioWorld Science

BioWorld Science
RSS

Investigational immunotherapy for Alzheimer's disease enters phase IIa

July 25, 2001

Neuroprotective agents designed at Nippon Kayaku attenuate paclitaxel-induced damage

July 24, 2001

Novel Genzyme intracellular delivery compounds particularly useful in gene therapy

July 24, 2001

Sankyo reveals naturally produced MPO inhibitors

July 24, 2001

Hydroxamic acid derivatives useful as antimicrobials

July 24, 2001

Dual 5-HT reuptake inhibitors and 5-HT1A agonists reported by Sumitomo in recent patent

July 24, 2001

Antibacterial platinum complexes discovered at Asahi Kasei

July 24, 2001

Patient enrollment completed in SafeScience phase II pancreatic cancer trial

July 24, 2001

VEGF inhibitors useful for angiogenesis-related disorders according to Yamanouchi

July 24, 2001

Vion's Triapine enters phase II for treatment of leukemia

July 24, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Wuxi Apptec insists it’s ‘not a Chinese military company’
BioWorld
Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...